Tuesday, November 4, 2025

SCHOTT Pharma accelerates self-administration and homecare with new 5.5 ml prefillable glass syringe for large-volume biologics

SCHOTT Pharma is setting a new milestone in self-administration and home therapy: the company has launched its first 5.5 ml prefillable staked-needle glass syringe. This new large-volume format, part of the syriQ BioPure® platform, is specifically designed for biologic drugs and is compatible with Ypsomed’s YpsoMate® 5.5 autoinjector.

With this innovation, SCHOTT Pharma addresses the growing demand for home administration of complex biologics, particularly in therapeutic areas such as immunology, oncology, and central nervous system disorders. The syringe enables safe, comfortable, and efficient injections outside of clinical environments.

“This portfolio expansion marks a significant step in advancing the trend of self-administering substantial drug doses at home,” says Andreas Reisse, CEO of SCHOTT Pharma. “With device-compatible large-volume options and collaborations with leading device manufacturers, we help pharmaceutical companies efficiently scale their homecare offerings and speed up time to market.”

The 5.5 ml syriQ BioPure® syringe is produced using specialized technology that ensures ultra-low tungsten levels, minimizing interaction between drug and container. Its design guarantees high compatibility with autoinjectors and consistent performance throughout the product lifecycle – key factors for reliable home administration of biologics.

By integrating SCHOTT Pharma’s new large-volume syringe into the YpsoMate® 5.5 autoinjector, Ypsomed strengthens its position in the large-volume segment. “This collaboration with SCHOTT Pharma underscores our shared mission to bring innovative, patient-friendly injection systems swiftly to market,” explains Ulrike Bauer, Chief Business Officer at Ypsomed.

The global market for large-volume injectors is expanding rapidly, driven by the rise of chronic diseases, technological innovation, and a shift toward cost-efficient, patient-centric homecare. SCHOTT Pharma positions itself as a strong partner in this transformation – providing solutions that improve access to advanced therapies.

From October 28–30, SCHOTT Pharma will showcase its full range of large-volume containment and delivery systems at the CPHI tradeshow in Frankfurt am Main, Germany.

With this launch, SCHOTT Pharma continues to pursue its mission of advancing patient care and innovation in drug delivery worldwide.